L65.1
Anagen effluvium
Clinical Classification Guidelines
Medical Intelligence & Overview
Anagen effluvium is a type of sudden hair loss that occurs during the growing phase of the hair cycle, known as the anagen phase. Unlike other forms of hair loss that develop gradually, anagen effluvium develops quickly and is characterized by widespread shedding of hair. It often results from medical interventions such as chemotherapy, radiation therapy, or exposure to certain toxins. This condition can cause significant hair thinning over a short period, sometimes leading to complete hair loss on the scalp and other body areas. Although distressing, hair loss from anagen effluvium is often reversible once the underlying cause is addressed or resolved.
Causes & Symptoms
Clinical Causes: Chemotherapy drugs used in cancer treatment Radiation therapy targeted at the scalp or neck Exposure to certain toxins or chemicals (e.g., arsenic, thallium) Severe acute illnesses or high fevers Sudden exposure to radiation or toxic substances Certain medications impacting rapidly dividing cells
Key Symptoms: Rapid hair loss, often within days to weeks of exposure to a cause Diffuse thinning across the scalp and sometimes other body hair Noticeable patches or complete baldness depending on severity Scalp may appear red or inflamed in some cases No significant scalp itching or burning, but shedding is abrupt Potential accompanying symptoms if caused by systemic illness
Diagnostic & Treatment
Diagnosis Path: Diagnosing anagen effluvium primarily involves a thorough medical history and physical examination. Healthcare providers may review recent treatments like chemotherapy or radiation. Dermoscopy—a skin surface microscopy—can help assess hair loss patterns. In certain cases, scalp biopsy might be performed to exclude other causes of hair loss, such as alopecia areata or telogen effluvium. Blood tests may also be ordered to evaluate for underlying infections or systemic conditions contributing to hair loss. Since the feature of rapid, diffuse hair loss is characteristic, diagnosis often relies on clinical presentation and history.
Treatment Protocols: Managing anagen effluvium involves addressing the underlying cause. If the hair loss is due to a medical treatment such as chemotherapy, hair generally regrows once treatment concludes and the hair cycle restarts. Supportive measures may include gentle scalp care, avoiding harsh hair treatments, and ensuring adequate nutrition. In some cases, medications like minoxidil are used to promote hair growth, though their effectiveness varies. Psychological support or counseling can help manage emotional distress caused by sudden hair loss. Preventive strategies, such as cooling caps during chemotherapy, have been studied to reduce hair loss severity. Overall, patience is essential, as hair tends to regrow over several months after the causative factor is removed or managed.
Clinical Advice & FAQs
Billing Guidance
Is L65.1 a billable ICD-10 code?
Yes, L65.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report L65.1?
Clinical documentation must specify the nature of Anagen effluvium and any associated comorbidities for accurate reporting.
Cite this Clinical Reference